Your browser doesn't support javascript.
loading
Normal cerebrospinal fluid concentrations of PDGFRß in patients with cerebral amyloid angiopathy and Alzheimer's disease.
De Kort, Anna M; Kuiperij, H Bea; Kersten, Iris; Versleijen, Alexandra A M; Schreuder, Floris H B M; Van Nostrand, William E; Greenberg, Steven M; Klijn, Catharina J M; Claassen, Jurgen A H R; Verbeek, Marcel M.
Afiliación
  • De Kort AM; Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Kuiperij HB; Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Kersten I; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Versleijen AAM; Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Schreuder FHBM; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Van Nostrand WE; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Greenberg SM; Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Klijn CJM; George & Anne Ryan Institute for Neuroscience, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island, USA.
  • Claassen JAHR; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Verbeek MM; Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, the Netherlands.
Alzheimers Dement ; 18(10): 1788-1796, 2022 10.
Article en En | MEDLINE | ID: mdl-34874603
BACKGROUND: Cerebrospinal fluid (CSF) platelet-derived growth factor receptor-ß (PDGFRß) has been proposed as a biomarker of blood-brain barrier (BBB) breakdown. We studied PDGFRß levels as a biomarker for cerebral amyloid angiopathy (CAA), amnestic mild cognitive impairment (aMCI), or Alzheimer's disease (AD). METHODS: CSF PDGFRß levels were quantified by enzyme-linked immunosorbent assay in patients with CAA, patients with aMCI/AD, and in matched controls. In aMCI/AD we evaluated CSF PDGFRß both by clinical phenotype and by using the AT(N) biomarker classification system defined by CSF amyloid (A), tau (T), and neurodegeneration (N) biomarkers. RESULTS: PDGFRß levels were similar in CAA patients and controls (P = .78) and in aMCI/AD clinical phenotype and controls (P = .91). aMCI/AD patients with an AD+ biomarker profile (A+T+[N+]) had increased PDGFRß levels compared to (A-T-[N-]) controls (P = .006). CONCLUSION: Our findings indicate that PDGFRß levels are associated with an AD+ biomarker profile but are not a suitable biomarker for CAA or aMCI/AD clinical syndrome.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Angiopatía Amiloide Cerebral / Enfermedad de Alzheimer / Disfunción Cognitiva Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Angiopatía Amiloide Cerebral / Enfermedad de Alzheimer / Disfunción Cognitiva Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos